CMS 121 capsule (25mg/cap) (30caps/bottle)

Unlock the potential of healthy aging with CMS121, a groundbreaking synthesized derivative of the flavonoid fisetin that targets age-related cognitive decline and metabolic disorders. This innovative compound acts as a potent fatty acid synthase (FASN) inhibitor, paving the way for remarkable preclinical benefits that could revolutionize how we address aging. Researchers have demonstrated that CMS121 effectively alleviates symptoms of Alzheimer’s disease in transgenic mice by modulating lipid metabolism and significantly reducing brain inflammation, offering a glimmer of hope for those affected by this debilitating condition.

In addition to its neurological benefits, CMS121 tackles the growing challenges of obesity and metabolic disorders. By inhibiting FASN, it enhances the body’s ability to maintain a balanced metabolism, making it easier to manage weight and improve overall health. This dual-action approach not only promotes cognitive resilience but also supports a healthier body, creating a synergistic effect that could change lives.

With its potent antioxidant properties, CMS121 safeguards brain cells from oxytosis and ferroptosis, two pathways implicated in cellular death and neurodegeneration. Embrace the future of preventative health and well-being with CMS121 — the key to unlocking vitality and enhancing quality of life as we age gracefully.

CMS121, a meticulously synthesized derivative of the flavonoid fisetin, emerges as a formidable candidate in the burgeoning field of geroneuroprotection and metabolic health. This compound exhibits multifactorial interactions within the cellular milieu, specifically as an inhibitor of fatty acid synthase (FASN). The inhibition of FASN is particularly salient, given its role in de novo lipogenesis and the perturbation of metabolic homeostasis, which are pivotal in the context of age-related cognitive degeneration and obesity-related syndromes. Notably, the preclinical investigations underscore its therapeutic potential in combating cognitive decline concomitant with aging, a phenomenon increasingly recognized as a complex interplay of neuroinflammation, oxidative stress, and altered lipid metabolism.

In a series of rigorously controlled preclinical studies utilizing transgenic murine models, CMS121 has demonstrably ameliorated the pathophysiological symptoms associated with Alzheimer’s disease. Through the modulation of lipid metabolic pathways and the mitigation of neuroinflammatory responses, CMS121 exhibits a dual capacity to attenuate synaptic dysfunction and enhance neuronal resilience. Importantly, its protective efficacy extends to counteracting mechanisms of oxytosis and ferroptosis — cellular demise modalities characterized by iron-dependent lipid peroxidation. The attenuation of these neurodegenerative processes not only signifies a promising frontier in pharmacological innovation but also invigorates the discourse surrounding targeted interventions in metabolic dysregulation associated with cognitive impairments. Hence, CMS121 may herald a paradigm shift in our therapeutic approach to neurodegenerative diseases and metabolic disorders, warranting further clinical exploration.